Quantel Medical announced last week that it has received approval from the U.S. Food and Drug Administration (FDA) for the Vitra 2® photocoagulator. Vitra 2® includes all the key elements that have made the success of the Vitra photocoagulator such as reliability, compactness and versatility. It also features a wide a range of improvements and new functionalities in terms of technology, clinically oriented software, and delivery systems.
Vitra 2® features a new generation of optimized laser cavity with an increased max power level. It is also now compatible with SingleSpot and MultiSpot technologies. The instrument features an easy to use clinically oriented software interface simplifying the treatment procedures and the doctors’ workflow thanks to printable treatment reports. Vitra 2® is also compatible with Haag Streit and Zeiss types slit lamps, with Quantel Medical YAG and YAG/SLT lasers and can be connected to a wide range of delivery systems (operating Microscopes, laser indirect ophthalmoscopes and laser probes).
“After a successful career spanning more than 13 years and with more than 3000 units sold worldwide, Quantel Medical is proud to announce the renewal of its 532nm flagship Vitra photocoagulator” said Jean-Marc Gendre, CEO Quantel Medical. “We are very excited to bring our new 532nm laser to ophthalmologists and their patients. Thanks to its flexibility and its ease of use, we are sure that more and more surgeons will embrace the MultiSpot technology delivery mode and its associated treatments benefits for retinal photocoagulation.”
Already launched in Europe in 2018, the Vitra 2® laser has already met its market across the various countries where it is commercialized.